Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNRHR | P30968 | 12/20 | 0.50 |
| ▸ | AR | P10275 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | RARG | P13631 | 1/20 | 0.33 |
| ▸ | RORC | P51449 | 1/20 | 0.33 |
| ▸ | CTSK | P43235 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6477952 | 0.81 | GNRHR (0.52) | GNRHRARLMNA | |
| SCHEMBL6478276 | 0.76 | GNRHR (0.82) | GNRHR | |
| SCHEMBL6478279 | 0.76 | GNRHR (0.82) | GNRHR | |
| SCHEMBL6476129 | 0.72 | ALDH1A1 (0.40) | GNRHRTP53MAPTLMNAALDH1A1 | |
| SCHEMBL6476891 | 0.68 | AR (0.47) | GNRHRARALDH1A1ADORA3 | |
| SCHEMBL6476552 | 0.67 | GNRHR (1.00) | GNRHR | |
| SCHEMBL6489326 | 0.65 | GNRHR (0.59) | GNRHR | |
| SCHEMBL6477411 | 0.64 | GNRHR (0.85) | GNRHR | |
| SCHEMBL6485600 | 0.63 | GNRHR (0.72) | GNRHR | |
| SCHEMBL6478272 | 0.62 | CES2 (0.34) | GNRHRLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6951858-B2 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2005-10-04 | — | — | US | disclosed |
| US-20050075339-A1 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2005-04-07 | — | — | US | disclosed |
| US-6673796-B2 | SEXUAL DISORDERS | NEUROCRINE BIOSCIENCES, INC. | 2004-01-06 | — | — | US | disclosed |
| US-20030114455-A1 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. | 2003-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114455-A1 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | GNRHR, GHRHR, LHCGR | GNRHR 1/4885AR 57/4885TP53 4090/4885 |
| US-20050075339-A1 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | GNRHR, LHCGR, GHRHR | GNRHR 1/4885AR 50/4885TP53 3397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.